Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
36.12
+0.59 (1.66%)
Nov 20, 2024, 4:00 PM EST - Market closed
Supernus Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 651.97 | 607.52 | 667.24 | 579.78 | 520.4 | 392.76 | Upgrade
|
| Revenue Growth (YoY) | 6.79% | -8.95% | 15.09% | 11.41% | 32.50% | -3.95% | Upgrade
|
| Cost of Revenue | 71.44 | 83.78 | 87.22 | 75.06 | 52.46 | 16.66 | Upgrade
|
| Gross Profit | 580.54 | 523.74 | 580.02 | 504.71 | 467.94 | 376.1 | Upgrade
|
| Selling, General & Admin | 335.46 | 336.36 | 377.22 | 304.76 | 200.68 | 153.25 | Upgrade
|
| Research & Development | 103.5 | 91.59 | 74.55 | 90.47 | 75.96 | 69.1 | Upgrade
|
| Operating Expenses | 519.75 | 510.34 | 534.4 | 425.22 | 292.34 | 227.52 | Upgrade
|
| Operating Income | 60.78 | 13.4 | 45.61 | 79.5 | 175.6 | 148.57 | Upgrade
|
| Interest Expense | - | -2.42 | -7.07 | -23.42 | -23.75 | -22.71 | Upgrade
|
| Interest & Investment Income | 13.21 | 10.45 | 21.68 | 10.22 | 14.35 | 21.32 | Upgrade
|
| EBT Excluding Unusual Items | 74 | 21.44 | 60.22 | 66.3 | 166.2 | 147.19 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.01 | 0.35 | 4.35 | 0.3 | Upgrade
|
| Asset Writedown | -20.19 | -20.19 | - | - | - | - | Upgrade
|
| Other Unusual Items | 6.67 | 1.52 | 0.51 | 6.53 | -1.9 | - | Upgrade
|
| Pretax Income | 72.48 | 2.77 | 60.74 | 73.18 | 168.65 | 147.49 | Upgrade
|
| Income Tax Expense | 12.77 | 1.45 | 0.03 | 19.75 | 41.7 | 34.43 | Upgrade
|
| Net Income | 59.71 | 1.32 | 60.71 | 53.42 | 126.95 | 113.06 | Upgrade
|
| Net Income to Common | 59.71 | 1.32 | 60.71 | 53.42 | 126.95 | 113.06 | Upgrade
|
| Net Income Growth | 133.05% | -97.83% | 13.64% | -57.92% | 12.29% | 1.86% | Upgrade
|
| Shares Outstanding (Basic) | 55 | 55 | 54 | 53 | 53 | 52 | Upgrade
|
| Shares Outstanding (Diluted) | 56 | 56 | 62 | 54 | 54 | 54 | Upgrade
|
| Shares Change (YoY) | -2.68% | -10.01% | 13.47% | 1.24% | -0.24% | -0.52% | Upgrade
|
| EPS (Basic) | 1.09 | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | Upgrade
|
| EPS (Diluted) | 1.07 | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 | Upgrade
|
| EPS Growth | 130.79% | -98.08% | 6.32% | -58.47% | 12.38% | 2.44% | Upgrade
|
| Free Cash Flow | 172.03 | 110.53 | 116.41 | 125.08 | 134.71 | 141.74 | Upgrade
|
| Free Cash Flow Per Share | 3.09 | 1.99 | 1.89 | 2.30 | 2.51 | 2.63 | Upgrade
|
| Gross Margin | 89.04% | 86.21% | 86.93% | 87.05% | 89.92% | 95.76% | Upgrade
|
| Operating Margin | 9.32% | 2.21% | 6.84% | 13.71% | 33.74% | 37.83% | Upgrade
|
| Profit Margin | 9.16% | 0.22% | 9.10% | 9.21% | 24.39% | 28.79% | Upgrade
|
| Free Cash Flow Margin | 26.39% | 18.19% | 17.45% | 21.57% | 25.89% | 36.09% | Upgrade
|
| EBITDA | 144.03 | 98.26 | 131.16 | 112.09 | 193.74 | 155.23 | Upgrade
|
| EBITDA Margin | 22.09% | 16.17% | 19.66% | 19.33% | 37.23% | 39.52% | Upgrade
|
| D&A For EBITDA | 83.25 | 84.86 | 85.54 | 32.6 | 18.14 | 6.66 | Upgrade
|
| EBIT | 60.78 | 13.4 | 45.61 | 79.5 | 175.6 | 148.57 | Upgrade
|
| EBIT Margin | 9.32% | 2.21% | 6.84% | 13.71% | 33.74% | 37.83% | Upgrade
|
| Effective Tax Rate | 17.61% | 52.47% | 0.05% | 26.99% | 24.72% | 23.35% | Upgrade
|
| Revenue as Reported | 651.97 | 607.52 | 667.24 | 579.78 | 520.4 | 392.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.